AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24974155 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 50 mg for 7 days
Number of subjects: 800
Study 24974155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 24974232 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of loop diuretics (furosemide)
Number of subjects: 82
Study 24974232 — intervention group
Group type: COMPARATOR
Intervention: Bolus treatment of loop diuretics (furosemide)
Number of subjects: 82
Study 24974301 — intervention group
Group type: EXPERIMENTAL
Intervention: Triathlon™ posterior stabilised cemented knee prosthesis
Number of subjects: 60
Study 24974301 — intervention group
Group type: COMPARATOR
Intervention: Triathlon™ cruciate retaining cemented knee prosthesis
Number of subjects: 60
Study 24974812 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery
Number of subjects: 0
Study 24974812 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification cataract surgery
Number of subjects: 0
Study 24975234 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary quality
Number of subjects: 0
Study 24975234 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported noise exposure
Number of subjects: 0
Study 24975234 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction between dietary quality and reported noise exposure
Number of subjects: 0
Study 24975273 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D₃ intervention
Number of subjects: 47
Study 24975800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol bronchial challenge (PD15 < 635 mg)
Number of subjects: 104
Study 24975800 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine bronchial challenge (PC20 < 16 mg/mL)
Number of subjects: 104
Study 24975800 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating curve analysis for mannitol
Number of subjects: 104
Study 24975800 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating curve analysis for methacholine
Number of subjects: 104
Study 24975800 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between log-transformed mannitol and methacholine response-dose ratios
Number of subjects: 104
Study 24975809 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg daily for a mean of 10.0 days (range: 2.0 to 39.0 days)
Number of subjects: 2733
Study 24975809 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg daily
Number of subjects: 2733
Study 24976801 — intervention group
Group type: EXPERIMENTAL
Intervention: Community psychiatry program (including psychiatrist appointments, individual and group therapy, enhanced access to psychiatric medications) for 1 year
Number of subjects: 156
Study 24976801 — intervention group
Group type: EXPERIMENTAL
Intervention: Community psychiatry program
Number of subjects: 156
Study 24976801 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cocaine and alcohol use disorder, current employment
Number of subjects: 156
Study 24977398 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 510
Study 24977398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 24977639 — intervention group
Group type: EXPERIMENTAL
Intervention: Eleveld allometric PK model using total body weight (TBW)
Number of subjects: 20
Study 24977639 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted body weight with Schnider and Marsh models
Number of subjects: 20
Study 24977639 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-compartment PK model linked to a sigmoidal inhibitory Emax PD model
Number of subjects: 20
Study 24977639 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated effect-site target of 3.2 μg/mL
Number of subjects: 20
Study 24977639 — intervention group
Group type: EXPERIMENTAL
Intervention: All tested PK models
Number of subjects: 20
Study 24977639 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Schnider and Marsh models
Number of subjects: 20
Study 24977639 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS response
Number of subjects: 20
Study 24978650 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 24978858 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous islet transplantation (ITx)
Number of subjects: 19
Study 24978858 — intervention group
Group type: COMPARATOR
Intervention: Oral antidiabetic drugs (OAD)
Number of subjects: 19
Study 24979126 — intervention group
Group type: EXPERIMENTAL
Intervention: Endolymphatic sac decompression surgery (ESDS)
Number of subjects: 67
Study 24979126 — intervention group
Group type: COMPARATOR
Intervention: Best available medical therapies (non-ESDS group)
Number of subjects: 67
Study 24979313 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced or standard CBT
Number of subjects: 94
Study 24979445 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz-containing regimen
Number of subjects: 5332
Study 24979445 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz-free regimen
Number of subjects: 5332
Study 24979578 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent depressive symptoms (Beck Depression Inventory score >10 at both times)
Number of subjects: 251
Study 24979578 — intervention group
Group type: COMPARATOR
Intervention: Patients without persistent depressive symptoms
Number of subjects: 251
Study 24980678 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image mediation
Number of subjects: 205
Study 24980678 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem mediation
Number of subjects: 205
Study 24980678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sobel's test for body image
Number of subjects: 205
Study 24980678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sobel's test for self-esteem
Number of subjects: 205
Study 24980704 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO criteria for GDM (fasting plasma glucose ≥ 7.0 mmol/L and/or 2-hour plasma glucose ≥ 7.8 mmol/L)
Number of subjects: 687
Study 24980704 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified IADPSG criteria (fasting glucose ≥ 5.1 mmol/L and/or 2-h plasma glucose ≥ 8.5 mmol/L)
Number of subjects: 687
Study 24981579 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based activities with on-site childcare and online support
Number of subjects: 36
Study 24982357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels in tumor tissue (IL8, GM-CSF, VEGF)
Number of subjects: 20
Study 24982357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels in serum (IL6)
Number of subjects: 20
Study 24982357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels correlated with TNM stage
Number of subjects: 20
Study 24982357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine levels correlated with NLR
Number of subjects: 20
Study 24982357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine profiles in different tissues
Number of subjects: 20
Study 24982357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine elevation reflects advanced disease
Number of subjects: 20
Study 24982674 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal-care dependency
Number of subjects: 296
Study 24982674 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 296
Study 24982681 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β estradiol (TBE)
Number of subjects: 20
Study 24982681 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17β estradiol (OBE)
Number of subjects: 20
Study 24982681 — intervention group
Group type: COMPARATOR
Intervention: Oral conjugated equine estrogen (OCEE)
Number of subjects: 20
Study 24983020 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HCV antibody testing
Number of subjects: 8500
Study 24983020 — intervention group
Group type: COMPARATOR
Intervention: Current HCV screening recommendations
Number of subjects: 8500
Study 24983206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 1995
Study 24983206 — intervention group
Group type: COMPARATOR
Intervention: Patients with comorbidities
Number of subjects: 1995
Study 24983206 — intervention group
Group type: COMPARATOR
Intervention: Patients with methicillin-resistant Staphylococcus aureus
Number of subjects: 1995
Study 24983206 — intervention group
Group type: COMPARATOR
Intervention: Patients requiring surgery
Number of subjects: 1995
Study 24983206 — intervention group
Group type: EXPERIMENTAL
Intervention: Modification of initial antibiotic treatment
Number of subjects: 1995
Study 24983346 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D-I (inadequate glycemic control)
Number of subjects: 35
Study 24983346 — intervention group
Group type: COMPARATOR
Intervention: T1D-A (adequate glycemic control)
Number of subjects: 35
Study 24983346 — intervention group
Group type: COMPARATOR
Intervention: CON-I (healthy controls)
Number of subjects: 35
Study 24983357 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF inhibitor (vemurafenib or dabrafenib/trametinib combination)
Number of subjects: 17
Study 24983357 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF inhibitor (PLX4720) and BCL-2 inhibitor (navitoclax)
Number of subjects: 17
Study 24983357 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF inhibitor (PLX4720) with BH3-mimetic (navitoclax)
Number of subjects: 17
Study 24983379 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term cold exposure (15 min exposure to temperature -10°C, wind 3 m/s, winter clothes)
Number of subjects: 51
Study 24984785 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 1 mg/cm²
Number of subjects: 0
Study 24984785 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 2 mg/cm²
Number of subjects: 0
Study 24984785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24985410 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol ER (100-250 mg bid)
Number of subjects: 4091
Study 24985410 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone CR (20-50 mg bid)
Number of subjects: 4091
Study 24985410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4091
Study 24986245 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-field endoscopic mucosal resection (WF-EMR)
Number of subjects: 1000
Study 24986638 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 14 weeks
Number of subjects: 1903
Study 24986638 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variations in glutamatergic-monoaminergic pathway
Number of subjects: 1903
Study 24986689 — intervention group
Group type: EXPERIMENTAL
Intervention: High 5-hydroxymethylcytosine (5hmC) levels
Number of subjects: 206
Study 24986689 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 5-hydroxymethylcytosine (5hmC) levels
Number of subjects: 206
Study 24986689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate 5-hydroxymethylcytosine (5hmC) levels
Number of subjects: 206
Study 24987412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar to sacral nerve rerouting
Number of subjects: 13
Study 24988120 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV ≥ 3.0 m/sec
Number of subjects: 572
Study 24988120 — intervention group
Group type: COMPARATOR
Intervention: TRV < 3.0 m/sec
Number of subjects: 572
Study 24988120 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP ≥ 160 pg/mL
Number of subjects: 572
Study 24988120 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TRV ≥ 3.0 m/sec and NT-proBNP ≥ 160 pg/mL
Number of subjects: 572
Study 24988449 — intervention group
Group type: EXPERIMENTAL
Intervention: GMI 1070
Number of subjects: 15
Study 24988476 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (oral medication)
Number of subjects: 0
Study 24990396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid maintenance dose (MD)
Number of subjects: 512
Study 24990396 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 10 mg MD
Number of subjects: 512
Study 24990396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg bid MD
Number of subjects: 512
Study 24990476 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 26
Study 24990578 — intervention group
Group type: EXPERIMENTAL
Intervention: New tuberculosis cases
Number of subjects: 0
Study 24990578 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously treated tuberculosis cases
Number of subjects: 0
Study 24990578 — intervention group
Group type: COMPARATOR
Intervention: Patients with diabetes, ≥3 previous TB episodes, ≥1 significant regimen change, and MDR-TB
Number of subjects: 0
Study 24990578 — intervention group
Group type: COMPARATOR
Intervention: Patients aged ≥35, BMI <18.5, diabetes, and MDR-TB
Number of subjects: 0
Study 24990578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cured cases at EOT with age ≥50 and BMI <18.5
Number of subjects: 0
Study 24990578 — intervention group
Group type: COMPARATOR
Intervention: Patients with treatment interruption
Number of subjects: 0
Study 24990822 — intervention group
Group type: EXPERIMENTAL
Intervention: SSc patients
Number of subjects: 45
Study 24990822 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP patients
Number of subjects: 45
Study 24990822 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 45
Study 24990822 — intervention group
Group type: EXPERIMENTAL
Intervention: SSc and PRP patients
Number of subjects: 45
Study 24990909 — intervention group
Group type: EXPERIMENTAL
Intervention: gE LIPS assay
Number of subjects: 0
Study 24990909 — intervention group
Group type: COMPARATOR
Intervention: viral capsid antigen ELISA
Number of subjects: 0
Study 24990909 — intervention group
Group type: COMPARATOR
Intervention: glycoprotein ELISA
Number of subjects: 0
Study 24990911 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A(H1N1) vaccine
Number of subjects: 122
Study 24990911 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 122
Study 24991041 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/d of folic acid (Pregnant Women)
Number of subjects: 26
Study 24991041 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/d of folic acid (Nonpregnant Women - NPW-0)
Number of subjects: 26
Study 24991041 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/d of folic acid (Nonpregnant Women - NPW-1)
Number of subjects: 26
Study 24991041 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d of folic acid (Nonpregnant Women - NPW-5)
Number of subjects: 26
Study 24991041 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 26
Study 24991041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant Women vs Nonpregnant Women
Number of subjects: 26
Study 24991089 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 204
Study 24991089 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe OSA (AHI > 5/hr TST)
Number of subjects: 204
Study 24991142 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic escitalopram
Number of subjects: 260
Study 24991142 — intervention group
Group type: COMPARATOR
Intervention: Lexapro
Number of subjects: 260
Study 24991893 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide
Number of subjects: 0
Study 24991893 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide + trastuzumab
Number of subjects: 0
Study 24991893 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study 24991893 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24992294 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg once daily
Number of subjects: 31
Study 24992294 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg once daily with tenofovir
Number of subjects: 31
Study 24992294 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir 300/100 mg once daily without tenofovir
Number of subjects: 31
Study 24992469 — intervention group
Group type: EXPERIMENTAL
Intervention: SSc-APAH
Number of subjects: 500
Study 24992469 — intervention group
Group type: COMPARATOR
Intervention: non-SSc-CTD-APAH
Number of subjects: 500
Study 24992948 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of 0.75 g L-alanine-L-glutamine for 24 hours
Number of subjects: 12
Study 24992948 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of 0.75 g L-alanine-L-glutamine for 5 days
Number of subjects: 12
Study 24993487 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone®/ethinyl estradiol contraceptive vaginal ring (CVR)
Number of subjects: 1036
Study 24993530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sebelipase alfa (1mg/kg or 3mg/kg) infused every-other-week
Number of subjects: 8
Study 24993951 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom graft designs
Number of subjects: 33
Study 24993951 — intervention group
Group type: COMPARATOR
Intervention: Noncustom graft designs
Number of subjects: 33
Study 24993987 — intervention group
Group type: EXPERIMENTAL
Intervention: Promus Element PtCr stents
Number of subjects: 337
Study 24994545 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term statin pretreatment
Number of subjects: 795
Study 24994545 — intervention group
Group type: COMPARATOR
Intervention: No statin pretreatment
Number of subjects: 795
Study 24995780 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic absence of both posterior communicating arteries (PCoAs)
Number of subjects: 38
Study 24995780 — intervention group
Group type: COMPARATOR
Intervention: Presence of at least 1 PCoA
Number of subjects: 38
Study 24996510 — intervention group
Group type: EXPERIMENTAL
Intervention: tVNS (transcutaneous vagus nerve stimulation)
Number of subjects: 50
Study 24996668 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudicated diagnosis of Acute Tubular Necrosis (ATN)
Number of subjects: 475
Study 24996668 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjudicated diagnosis of Pre-renal Azotemia (PRA)
Number of subjects: 475
Study 24996668 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement among reviewers
Number of subjects: 475
Study 24996765 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Change (ToC) approach
Number of subjects: 0
Study 24996961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification intervention; details on dosage and duration not available.
Number of subjects: 0
Study 24996961 — intervention group
Group type: COMPARATOR
Intervention: Control group; details on intervention not available.
Number of subjects: 0
Study 24997153 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox at a starting dose of 10 mg/kg/day for 52 weeks
Number of subjects: 30
Study 24997153 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox therapy continued
Number of subjects: 30
Study 24997153 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox therapy discontinued
Number of subjects: 30
Study 24997153 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 30
Study 24997328 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosponge
Number of subjects: 20
Study 24997328 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy
Number of subjects: 20
Study 24997723 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive image-guided breast brachytherapy (NIBB)
Number of subjects: 40
Study 24997880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cysteamine bitartrate (60 mg/kg per day) and N-acetylcysteine (60 mg/kg per day)
Number of subjects: 9
Study 24997880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cysteamine bitartrate and N-acetylcysteine
Number of subjects: 9
Study 24999380 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare variants of GABRB3 in patients with ASD
Number of subjects: 356
Study 24999380 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare variants at the 5' regulatory region
Number of subjects: 356
Study 24999380 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporter gene assays of rare variants
Number of subjects: 356
Study 24999380 — intervention group
Group type: COMPARATOR
Intervention: Common SNPs
Number of subjects: 356
Study 25000939 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV infection
Number of subjects: 242
Study 25000939 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk HPV types
Number of subjects: 242
Study 25000939 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16
Number of subjects: 242
Study 25000939 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-18
Number of subjects: 242
Study 25000939 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-31
Number of subjects: 242
Study 25000939 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-45
Number of subjects: 242
Study 25000939 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-52
Number of subjects: 242
Study 25000939 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV distribution by age
Number of subjects: 242
Study 25000939 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 infection in ICC stage II or greater
Number of subjects: 242
Study 25000939 — intervention group
Group type: EXPERIMENTAL
Intervention: Single type infection
Number of subjects: 242
Study 25000939 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple infections
Number of subjects: 242
Study 25001321 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab (0.5 mg)
Number of subjects: 56
Study 25001321 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab (1.25 mg)
Number of subjects: 56
Study 25001321 — intervention group
Group type: EXPERIMENTAL
Intervention: aflibercept (2.0 mg)
Number of subjects: 56
Study 25001524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m² i.v. Q3W plus oral prednisone/prednisolone 10 mg daily
Number of subjects: 153
Study 25002028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CDK 4/6 inhibitors and PI3K inhibitors
Number of subjects: 0
Study 25002028 — intervention group
Group type: COMPARATOR
Intervention: Single-agent PI3K inhibitors
Number of subjects: 0
Study 25002028 — intervention group
Group type: COMPARATOR
Intervention: PI3K inhibitor BYL719
Number of subjects: 0
Study 25002028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PI3K and CDK 4/6 inhibitors
Number of subjects: 0